目的:探讨阿替普酶静脉溶栓后早期应用替罗非班治疗急性缺血性脑卒中(AIS)患者的效果.方法:选2019年11月-2020年11月于大庆龙南医院接受治疗的AIS患者90例,收集其临床资料开展本研究.AIS患者均接受静脉阿替普酶溶栓治疗,依据溶栓后替罗非班用药时间的差异分组,各45例.对照组在溶栓后7～12 h启用替罗非班,研究组在溶栓后2～7 h启用替罗非班.对比两组临床疗效、不同时间点NIHSS评分、预后(mRS评分)、日常生活能力与运动功能评分以及不良事件发生情况.结果:研究组治疗有效率高于对照组(P<0.05);溶栓前及溶栓后2 h时,两组NIHSS评分比较,差异均无统计学意义(P>0.05);在替罗非班治疗完毕及溶栓后1周时研究组NIHSS评分均明显低于对照组(P<0.05).溶栓前两组患者的mRS评分比较,差异无统计学意义(P>0.05);治疗后3个月两组mRS评分均较溶栓前下降,研究组mRS评分低于对照组(P<0.05).治疗前两组患者日常生活能力与运动功能评分比较,差异均无统计学意义(P>0.05);治疗后3个月,两组日常生活能力与运动功能评分均较治疗前改善,且研究组日常生活能力与运动功能评分均高于对照组(P<0.05).研究组患者再闭塞、症状性颅内出血、非症状性颅内出血、其他部位出血的总发生率为6.7％,低于对照组的24.4％(P<0.05).结论:对AIS患者使用阿替普酶静脉溶栓后,实施早期(溶栓后2～7 h)应用替罗非班治疗,可促进临床疗效提升,改善神经功能缺损程度,提升患者日常生活能力与运动功能,降低两组不良事件发生情况,值得应用.

目的:研究艾地苯醌和尼莫地平联合用于脑梗死后血管性认知功能障碍的价值.方法:2018年1月-2019年12月本科接诊脑梗死后血管性认知功能障碍病患60例,随机均分2组.研究组联用艾地苯醌和尼莫地平,对照组单用尼莫地平.对比不良反应等指标.结果:针对不良反应发生率,研究组3.33％,和对照组13.33％比较无显著差异,P>0.05.针对总有效率,研究组96.67％,比对照组80.0％高,P<0.05.结论:于脑梗死后血管性认知功能障碍中联用艾地苯醌和尼莫地平,不良反应少,疗效显著.

Objectives: The nerve damage and cognitive impairment caused by intracerebral hemorrhage (ICH) seriously affect the quality of life of patients. Cordycepin has been reported to have antioxidant and neuroprotective functions. However, the therapeutic effect of cordycepin on cognitive impairment caused by ICH is still unclear. Materials and methods: Autologous whole blood was injected into the basal ganglia to construct a mouse ICH model. The Modified Neurological Severity Score was used to assess nerve damage in mice. The wet/dry method was used to detect brain water content. Open field test was used to assess the anxiety of mice. Morris water maze testing, Y-maze test and nest-building test were used to evaluate the cognitive function of mice. qRT-PCR and western blotting assay were used to evaluate the expression of genes. Results: Cordycepin treatment could ameliorate ICHinduced neurological deficits, brain edema, anxiety, cognitive impairments, oxidative stress and antioxidant capacity in ICH mice. Conclusion: Cordycepin ameliorates ICH-induced neurological and cognitive impairments through reducing anti oxidative stress in mouse model.

目的:此次研究中针对急性脑梗死后脑出血病症而言,应用阿替普酶药物的临床治疗效果是否可达到预期状态进行具体分析和论述,同时明确与NHISS评分之间的联系,以期为相关领域从业人员提供一定理论指导.方法:选取收治时间范围在2017年9月至2018年9月一年时间内接受治疗的60名急性脑梗死病患为主要研究对象,按照研究期间应用治疗方式差异性将其分作两个对比小组,对比不同的指标数据.结果:两组病患接受差异性治疗后的详细指标数据比对内容见正文表格处,通过表格可以看出,均是应用阿替普酶药物展开治疗的观察组30名急性脑梗死病患数据占优势,两组数据比对有明显的差异.结论:通过此次研究数据比对可以看出,临床期间对于急性脑梗死后脑出血病症而言,通过阿替普酶药物的应用可在一定程度上显著强化病患神经功能异常的改善治疗效果,并且用药安全性较高,治疗后出现发生率和NHISS评分有密切联系.因而就需要医师在治疗期间,不止要重视病患脑梗死症状的针对性医治,还要强化其他不同系统疾病的诊治.阿替普酶药物的效果较好,值得相关领域的深入研究和广泛应用.

目的 通过对晚期帕金森患者进行观察,采用普拉克索与美多芭进行患者治疗,探究其临床效果与用药安全性.方法 参与本次研究的帕金森患者其就诊时间在2017-2018年近1年内,共计患者60例.以临床治疗方式不同对患者进行随机分组,其中一般组通过采用美多芭进行患者的治疗.对于观察组患者在一般组的基础上采用普拉克索进行治疗.结果 对60名晚期帕金森患者进行了临床治疗研究,30名观察组患者的治疗成效高于对照组的治疗成效.30名观察组患者中,有18名患者的治疗成效比较显著,有9名患者的治疗成效一般,有3名患者的治疗结果无效.30名对照组患者中,有6名患者的治疗效果比较显著,有9名患者的治疗效果一般,有15名患者的治疗没有成效.两组的治疗成效差异具有统计学的意义,p<0.05.结论 在目前来说普拉克索与美多芭能够有效缓解患者的临床症状,减少了不良情况的发生,临床价值较为优良.

目的:通过对癫痫患者进行治疗,采用拉莫三嗪联合小剂量丙戊酸的方式,对其临床效果进行探究.方法:选取参与本次研究的80例癫痫患者,其就诊及收治时间在2017.1-2018.1月近连三年间.随后根据单双号进行患者的随机分组,两组癫痫病患者首先均给予丙戎酸治疗,其对于观察组患者来说,在一般组治疗的基础上结合拉莫三嗪治疗.结果:一般组整体有效人数为29例,所占比例为72.5％.观察组整体有效人数为38例,所占比例为95.0％.结论:采用小剂量丙戊酸联合拉莫三嗪具有一定的治疗效果和应用价值.

目的:分析血塞通+依达拉奉治疗脑梗塞患者的临床疗效观察及有效性.方法:此次研究全部选取的是17-18年在我们医院接受医治的脑梗塞患者,我们随便的选择了60例之后,将他们划分成两组,对照组患者采用比较常规的方法进行医治.观察组在常规的医治方法上使用血塞通配合依达拉奉进行医治.结果:两组患者在医治前的全血浆粘度、血小板凝聚率、血栓形成系数是没有差别的,没有统计学差异,但是在血塞通配合依达拉奉的医治后可以清晰地看见,观察组患者的血液的粘连度有了很好的明显的改善,但是对照组患者的医治效果就没与那么好.根据数据可以看出两组患者在医治之前没有很大的差异,但是在医治之后,观察组的评分很明显的提高了.在两组患者医治前后,数据差异具有统计学意义,P<0.05.结论:综上所述,血塞通配合依达拉奉医治脑梗塞的效果十分的明显,这两者药物的医治可以非常有效的改善患者的血液粘连度,提高患者的血液流动,甚至对于提高脑梗塞患者医治后的日常生活能力也有非常有力的效果,可以推广使用.

Objective To investigate the effect of atorvastatin in the treatment of patients with cerebral infarction. Methods One hundred and fourteen patients with cerebral infarction were selected in the hospital from October 2009 to October 2011, who were randomly divided into two groups. Fifty-seven patients used conventional treatment as the control group. On the basis of routine treatment, 57 patients used atorvastatin (20 mg/time, 1 time/d, oral 14 d) in the treatment as the observation group. Course of treatment was two weeks. Clinical indicators and the scores of neurological deficit were compared between two groups after treatment. Results Hypersensitive C reactive protein levels, levels of matrix metalloproteinase-9, the scores of neurological deficit, recurrence rate in the observation group were significantly lower than those in the control group. Patient satisfaction in the observation group was significantly higher than that in the control group. The difference was statistically significant (P 0.05). Conclusion Atorvastatin in the treatment for patients with cerebral infarction has obvious curative effect, which not only can reduce inflammation in the body and improve atherosclerotic condition of patients, but also can improve the neurological function. That is worthy of clinical use.

Objective To investigate the clinical efficacy on high dose mecobalamin and pancreatic kininogenase in the treatment of diabetic peripheral nerve damage recovery. Methods Sixty four patients with diabetic peripheral nerve damage were selected in the hospital from November 2008 to November 2011, who were randomly divided into two groups. 32 patients used Vitamin B12 (muscle injection, 0.5 mg/time, 1 time/d, course of 14 d) and pancreatic kininogenase (oral, 120 U/time, 3 times/d, course of 14 d ) in the treatment as the control group. 32 patients used mecobalamin (intravenous infusion,1 500 μg/250 mL saline, 1 time/d, course of 14 d ) and pancreatic kininogenase in the treatment as the observation group. Clinical efficacy and nerve conduction velocity were compared between two groups after the treatment. Results Total effective rate in the observation group (96.9%) was significantly higher than that in the control group (59.4%). The motor nerve conduction velocity and sensory nerve conduction velocity in the observation group were significantly higher than those in the control group. The difference was statistically significant (P 0.05). The incidence of adverse reactions in the observation group (12.5%) was higher than that in control group (3.1%). The difference was not statistically significant (P 0.05). Conclusion High dose mecobalamin and pancreatic kininogenase in the treatment for diabetic peripheral nerve damage has significant clinical efficacy, which can obviously improve the nerve conduction velocity. The incidence of adverse reaction is lower. It is worthy of clinical use.

Objective To investigate the clinical efficacy of edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction. Methods Seventy-six patients with acute progressive cerebral infarction were selected in the hospital from November 2009 to December 2011, who were randomly divided into two groups. 38 patients used low molecular weight heparin in the treatment as the control group, 38 patients used edaravone and low molecular weight heparin in the treatment as the observation group. Clinical indicators and the scores of neurological deficit were compared between two groups after treatment. Results Activated partial thromboplastin time in the observation group was (32.5±7.1) s, which was longer than (31.0±6.2) s in the control group, while the difference was not statistically significant (P 0.05). Platelet counts and the total efficiency in the observation group were (184.2±29.6)×109/L and 76.3%, respectively, which were significantly higher than (146.7±31.4)×109/L and 52.6% in the control group. Fibrinogen level, neuron specific enolase levels, the scores of neurological deficit in the observation group were (2.9±0.7) g/L, (10.7±2.9) μg/L, (10.7±2.8), respectively, which were significantly lower than (3.3±1.4) g/L, (21.6±4.1) μg/L, (18.2±4.6) in the control group. The differences were statistically significant (P 0.05). Conclusion Edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction can obviously improve the neurological function, which is safe and effective.